Metrics other than potency reveal systematic variation in responses to cancer drugs.

[1]  E. Borden,et al.  Phase I trials of targeted anticancer drugs: a need to refocus , 2012, Nature Reviews Drug Discovery.

[2]  V. Quaranta,et al.  Fractional Proliferation: A method to deconvolve cell population dynamics from single-cell data , 2012, Nature Methods.

[3]  Michael J. Keiser,et al.  Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.

[4]  Peter K. Sorger,et al.  Exploring the Contextual Sensitivity of Factors that Determine Cell-to-Cell Variability in Receptor-Mediated Apoptosis , 2012, PLoS Comput. Biol..

[5]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[6]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[7]  Timothy J. Mitchison,et al.  The proliferation rate paradox in antimitotic chemotherapy , 2012, Molecular biology of the cell.

[8]  Joshua M. Stuart,et al.  Subtype and pathway specific responses to anticancer compounds in breast cancer , 2011, Proceedings of the National Academy of Sciences.

[9]  Mario Niepel,et al.  Adaptive informatics for multi-factorial and high content biological data , 2011, Nature Methods.

[10]  Lin Shen,et al.  Dose–response curve slope is a missing dimension in the analysis of HIV-1 drug resistance , 2011, Proceedings of the National Academy of Sciences.

[11]  Joel Greshock,et al.  Molecular target class is predictive of in vitro response profile. , 2010, Cancer research.

[12]  K. Shokat,et al.  Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. , 2010, Cancer cell.

[13]  J. Dancey.  mTOR signaling and drug development in cancer , 2010, Nature Reviews Clinical Oncology.

[14]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[15]  Laura Tolosi,et al.  Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. , 2009, The Journal of clinical investigation.

[16]  P. Sorger,et al.  Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.

[17]  Robbie Loewith,et al.  Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 , 2009, PLoS biology.

[18]  R. Milo,et al.  Dynamic Proteomics of Individual Cancer Cells in Response to a Drug , 2008, Science.

[19]  R. Germain,et al.  Variability and Robustness in T Cell Activation from Regulated Heterogeneity in Protein Levels , 2008, Science.

[20]  Lin Shen,et al.  Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs , 2008, Nature Medicine.

[21]  R. Milo,et al.  Variability and memory of protein levels in human cells , 2006, Nature.

[22]  R. Shoemaker.  The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[23]  I. Shih,et al.  Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. , 2006, Cancer research.

[24]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[25]  M K Markey,et al.  Application of the mutual information criterion for feature selection in computer-aided diagnosis. , 2001, Medical physics.

[26]  J. Mesirov,et al.  Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Terry L Riss,et al.  CELLTITER-GLO™ LUMINESCENT CELL VIABILITY ASSAY: A SENSITIVE AND RAPID METHOD FOR DETERMINING CELL VIABILITY , 2001 .

[28]  James N. Weiss.  The Hill equation revisited: uses and misuses , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[30]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[31]  P. Russell,et al.  A role for Hsp90 in cell cycle control: Wee1 tyrosine kinase activity requires interaction with Hsp90. , 1994, The EMBO journal.

[32]  A. Murray,et al.  Cyclin is degraded by the ubiquitin pathway , 1991, Nature.

[33]  Thomas M. Cover,et al.  Elements of Information Theory , 2005 .

[34]  I. Jolliffe.  Principal Component Analysis , 2005 .

[35]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[36]  T. Chou,et al.  Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. , 1976, Journal of theoretical biology.

[37]  Berenbaum Mc,et al.  In vivo determination of the fractional kill of human tumor cells by chemotherapeutic agents. , 1972 .

[38]  M C Berenbaum,et al.  In vivo determination of the fractional kill of human tumor cells by chemotherapeutic agents. , 1972, Cancer chemotherapy reports.

[39]  A. Hill,et al.  The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .